Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 6.31% in its stock price, closing at $13.96, while the S&P 500 gained 0.4% [1] - Over the past month, the company's shares have increased by 55.05%, significantly outperforming the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61% [1] Earnings Projections - The upcoming earnings disclosure for Ginkgo Bioworks is projected to show an earnings per share (EPS) of -$1.44, which reflects a 55% increase from the same quarter last year [2] - Revenue is estimated to be $43 million, indicating a 23.5% decrease compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict an EPS of -$5.56 and revenue of $180 million, representing changes of +46.33% and -20.72% from the previous year, respectively [3] - Recent changes to analyst estimates for Ginkgo Bioworks are important as they indicate the evolving nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasetsBOSTON, July 17, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of a powerful new capability at Ginkgo Datapoints: high-throughput, low-cost ADME (Absorption, Distribution, Metabolism, and Excretion) profiling, enabled by Ginkgo's proprietary RAC automatio ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $9.60, demonstrating a +1.8% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.32% for the day. On the other hand, the Dow registered a gain of 0.53%, and the technology-centric Nasdaq increased by 0.26%. Shares of the company have appreciated by 10.29% over the course of the past month, outperforming the Medical sector's loss of 3.4%, and the S&P 500's gain of 4.51%.Market part ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.79, reflecting a -2.53% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.28% [1] - The stock has increased by 13.19% over the past month, outperforming the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Projections - The upcoming EPS for Ginkgo Bioworks is projected at -$1.44, indicating a 55.00% increase compared to the same quarter last year [2] - Quarterly revenue is estimated at $43 million, which is a decrease of 23.5% from the year-ago period [2] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively compared to the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they reflect short-term business trends and can indicate analyst optimism about the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, provides an actionable rating system for investors [5] - Ginkgo Bioworks currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6] Industry Context - Ginkgo Bioworks is part of the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [7]

Meta Platforms, Inc. META CEO Mark Zuckerberg has made a decisive move to reshape the company's entire AI strategy by consolidating all artificial intelligence efforts under a newly formed division called Meta Superintelligence Labs. The restructuring aims to drive Meta toward its goal of creating superintelligence—AI systems that surpass human cognitive abilities. Read Next: What Happened With Apple Stock Today? Unified AI Leadership and Vision Zuckerberg has been deeply involved in recruitment and reporte ...

Ginkgo Bioworks Holdings, Inc. (DNA) shares rallied 18.9% in the last trading session to close at $11.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the potential of Ginkgo’s proprietary cell programming platforms, Foundry and Codebase. The company offers R&D services ut ...

Core Insights - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls, surpassing Regeneron Pharmaceuticals' previous offer of $256 million in a bankruptcy auction [1][2] - The deal is expected to close soon, pending a court hearing scheduled for June 17 [1] - 23andMe filed for bankruptcy in March due to declining demand and a data breach in 2023 that compromised sensitive customer information [2][6] Company Developments - 23andMe's bankruptcy filing was a result of a significant decline in consumer demand for DNA testing services [2][6] - The company faced legal challenges, with New York and over two dozen other states suing to contest the sale of its customers' private information [3] - TTAM Research Institute, associated with Wojcicki, has committed to upholding 23andMe's existing privacy policies and complying with data protection laws [2] Competitive Landscape - Regeneron Pharmaceuticals initially offered $256 million for 23andMe, which was later outbid by Wojcicki's nonprofit [1][5] - Regeneron expressed willingness to make a new bid but requested a $10 million breakup fee if Wojcicki's bid is accepted [5]

Core Viewpoint - Ginkgo Bioworks announces the resignation of CFO Mark Dmytruk, effective May 30, 2025, with Steven Coen appointed as the new CFO, highlighting a leadership transition aimed at continuing the company's financial strategy and goals [1][3]. Company Leadership Transition - Mark Dmytruk will resign to pursue another opportunity, and Steven Coen, who joined Ginkgo on May 1, 2023, will take over as CFO [1][2]. - Coen brings over 30 years of experience in public accounting and corporate finance, previously serving as Corporate Vice President and Corporate Controller at Charles River Laboratories, which has annual revenues of approximately $4.0 billion [2]. Financial Strategy and Goals - Coen expressed confidence in continuing the financial vision established by Dmytruk, focusing on cost reduction targets and achieving Adjusted EBITDA breakeven by the end of 2026 [3]. - Dmytruk acknowledged the high-performing finance organization he built and expressed confidence in Coen and the finance team to advance the company's financial objectives [3]. Company Overview - Ginkgo Bioworks is a leading platform for cell programming, providing services across various markets, including food, agriculture, pharmaceuticals, and biosecurity [4].

Core Insights - Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, which includes its personal genome service, total health, research services, and biobank of genetic samples [1] - 23andMe will continue to provide consumer genome services post-acquisition [1] Group 1: Acquisition Details - The acquisition aims to enhance 23andMe's mission of helping individuals understand their DNA and improve personal health, while also supporting Regeneron's genetic research initiatives [2] - The deal is expected to close in the third quarter of this year, with Regeneron required to adhere to 23andMe's privacy policies regarding customer data [3] Group 2: Company Background - 23andMe filed for Chapter 11 bankruptcy protection in March, leading to the immediate resignation of CEO Anne Wojcicki [4] - The company, which went public in 2021 with a valuation of $6 billion, has struggled to achieve profitability and faced significant challenges, including a $30 million settlement for a data breach and substantial layoffs [5] - As of November, 23andMe reported debts of $2.3 billion and approximately $126 million in cash and cash equivalents, indicating a need for additional liquidity [5]

Financial Performance & Targets - Ginkgo achieved $205 million in annual run-rate cost savings from Q1 2024 to Q1 2025[13] - The company maintains a strong financial position with $517 million in cash, cash equivalents, and marketable securities[15] - Total Adjusted EBITDA improved from $(117) million in Q1 2024 to $(47) million in Q1 2025, a 59% increase[34] - Ginkgo is targeting Adjusted EBITDA breakeven by the end of 2026[11, 49] - The company aims for $250 million of annualized run-rate savings target by the end of Q3 2025[53] Revenue & Growth - Cell Engineering revenue increased by 37% year-over-year, reaching $38 million in Q1 2025[34] - This includes recognition of $75 million non-cash deferred revenue from BiomEdit[24] - Total revenue increased by 27% year-over-year, from $38 million to $48 million[34] - Biosecurity revenue remained stable at $10 million in Q1 2025 compared to Q1 2024[34] Biosecurity Expansion - Ginkgo's biosecurity segment has expanded its reach to 127 countries of origin of flights sampled, representing 65% of nations globally[33] - The biosecurity network includes 11 key international airports and 45 collection nodes cumulatively in 2025[33]